Why Q32 Bio Stock Skyrocketed Today
The biotech is advancing a potential treatment for a common autoimmune disease.
Overview
Shares of Q32 Bio (NASDAQ: QTTB) soared on Monday after the biotechnology company announced promising clinical trial results for its experimental hair loss treatment.
Image source: Getty Images.
A Phase 2a clinical study of Q32 Bio's investigational antibody treatment, bempikibart, in patients with severe or very severe alopecia areata met its primary efficacy goal.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.